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Introduction
Drug induced liver injury is the most frequent reason cited for market-withdrawal of approved drugs (Lee, 2003) . In order to detect hepatotoxic effects as early as possible in the process of drug development, in vitro liver models, such as primary hepatocytes, are increasingly being used Gomez-Lechon et al., 2010) . Primary hepatocytes have been shown to be the most relevant model for predicting in vivo xenobiotic metabolism (Blanchard et al., 2005; Foster et al., 2011) , drug-drug interaction through a reversible or time-dependent inhibition of CYP450s (Zhao et al., 2005; Soars et al., 2007; Gomez-Lechon et al., 2010) , interference with transporters (Soars et al., 2007; De Bruyn et al., 2011) and for drug toxicity Liguori et al., 2005; Li, 2009 ).
Microarray analysis has great utility for the elucidation of underlying mechanisms of hepatotoxicity (Richert et al., 2008; Lauer et al., 2009 ). In addition, large inter-individual variability has been observed in both the basal expression (Rogue et al., 2012) and in response to treatment of many genes related to drug metabolism: Liguori at al., (2005) showed that after 24 hours treatment of trovofloxacin, gene changes varied across four different primary human hepatocytes (PHH) cultures.
We (Abadie-Viollon et al., 2010) have shown an important inter-donor variability in the response of three PHH cultures to a 72-hour exposure to reference CYP450 inducers, and Goyak et al. (2008) reported that only a small set of genes was consistently deregulated across ten PHH cultures, whereas relatively large gene sets were regulated uniquely in a given PHH culture in response to 24 hours exposure to reference inducers.
To date mainly short-term exposure in vitro toxicity studies have been reported (Lauer et al., 2009; Gerets et al., 2012) , but effects in humans during long-term medication needs also to be evaluated and thus long-term repeat-dose toxicity assessments in in vitro systems need to be performed. The expression of many liver-specific genes decrease during the initial stage of cultivation of PHHs (Boess et al., 2003; Richert et al., 2006) , often associated with declines in metabolic capacities (Richert et al., 2002; Binda et al., 2003; Madan et al., 2003) . They are however maintained at acceptable levels over time in long-term cultures using sandwich configuration and appropriate medium (Hewitt et al., 2007;  This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on August 2, 2013 as DOI: 10.1124/dmd.113.052415 at ASPET Journals on June 22, 2017 dmd.aspetjournals.org Downloaded from Tuschl et al., 2009; Mueller et al., 2012) . Prolonged exposure studies of PHH to drugs affecting major toxicity and metabolism pathways, such as ethanol during 14 days (van Pelt et al., 2003) or diclofenac during 23 days (Mueller et al., 2012) have indicated a good in vivo / in vitro correlation.
Chlorpromazine (CPZ) is the most widely used phenothiazine neuroleptic for the treatment of schizophrenic patients (Wojcikowski et al., 2010) . CPZ clearance was demonstrated to be dependent on the patient's bodyweight and lifestyle which is a major problem for its therapeutic use (Pantuck et al., 1982; Chetty et al., 1994 ). An inter-donor CYP450 polymorphism is also recognized for CPZ pharmacokinetics, since it is extensively metabolized by CYP2D6 and CYP1A2 (Yeung et al., 1993; Yoshii et al., 2000) . CPZ has been reported to be cytotoxic and several of its metabolites, generated by both rat and human metabolism, are known to be equally or more cytotoxic than CPZ itself (Abernathy et al., 1977; Tavoloni and Boyer, 1980; Yeung et al., 1993) . A species-difference in the in vitro sensitivity of hepatocytes in monocultures has been reported, with an EC 50 as low as 9 ± 6 µM CPZ in human (Gerets et al., 2012) compared to 110 µM in rat (Zhang et al., 2011) hepatocytes. An incidence of 1-2 % cholestasis has been reported in patients treated with CPZ at therapeutic doses of 2 to 5 mg/kg (Boelsterli et al., 1987; Horikawa et al., 2003; de Abajo et al., 2004) . In contrast, CPZ was not hepatotoxic in pre-clinical toxicity studies: for example, CPZ did not cause cholestasis after 3 week repeated-dosing at the highest dose level of 20 mg/kg in rats (Tsao et al., 1983) . More recently, Buchweitz et al. (2002) demonstrated the appearance of cholestasis in rats after one dose of CPZ (70mg/kg bodyweight) given 2 hours after LPS administration. Involvement of an inflammatory process could indeed underlie the idiosyncrasy of CPZ since, in humans, CPZ-induced cholestasis has been associated with an infiltration of inflammatory cells, such as neutrophils and lymphocytes (Moradpour et al., 1994) .
In the present study the mRNA expression profile of PHH's was analyzed after single-and repeat-dose treatment of CPZ, with the aim to address mechanisms as well as inter-individual variability of PHH.
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Material and methods
Chemicals and solutions
William's E medium GlutaMAX TM , fetal bovine serum (FBS), insulin-transferrin-selenium (ITS), sodium pyruvate, gentamycin and Geltrex TM were purchased from Invitrogen (Fisher, Illkirch, France).
Insulin, penicillin/streptomycin, dexamethasone, bovine serum albumin, dimethyl sulfoxide (DMSO), Percoll®, collagenase and chlorpromazine hydrochloride were from Sigma-Aldrich (St-QuentinFallavier, France). Hepatocyte maintenance medium (HMM™) was from Lonza (Verviers, Belgium).
Isolation of primary human hepatocytes (PHH)
Human liver tissue was obtained from resections from patients undergoing partial liver hepatectomy for therapy of hepatic tumors, with permission of the national ethics committees and regulatory authorities (Table 1 ). Biopsies (20-100 g) were removed from the safety margin of the tissue resected near the tumor. Human hepatocytes were isolated using a two-step perfusion technique as previously described by Richert et al. (2004) and Lecluyse and Alexandre (2010) . Briefly, two to four hepatic vessels were cannulated and perfused with 0.5 mM EGTA-containing buffer for 10 min and then with a 0.02 % collagenase-containing buffer for 20 min at 37°C. At the end of the perfusion, the resection was removed from the perfusion system and immersed into warm HBSS containing 10 % FBS (suspension buffer). Using tissue forceps and scissors, the Glisson's capsule was gently torn and the hepatocytes released into the medium following gentle shaking and passing the tissue between the tissue forceps, leaving behind the connective tissue and any undigested material. The cells were filtered through 850, 400 and 100 µm meshes and then centrifuged at 80 g for 5 min at room temperature (RT). Cells were washed once in suspension buffer and once in Percoll ® -containing buffer (final concentration 28.8 %) at 168 g for 20 min at RT. The hepatocytes were washed again in suspension buffer at 80 g for 5 min at RT and cell viability and number were determined using the Trypan blue (0.4 %) exclusion method. Only preparations with more than 70 % cell viability were used for further experiments.
Exposure to CPZ for cell viability
This article has not been copyedited and formatted. The final version may differ from this version. an emission wavelength at 590 nm. For the MTT assay, cell monolayers were incubated for 30 min with thiazolyl blue tetrazolium bromide (1 mg/mL), the supernatant was removed and 100 µL per well of DMSO was added. After gentle shaking, the absorbance was measured at 595 nm. For the two assays, results were expressed as a percentage versus the vehicle control.
Culture and exposure to CPZ for transcriptomic analysis
The PHH suspension obtained after isolation was seeded as described in "Exposure to CPZ for cell viability" onto collagen I coated 6-well plates (Biocoat ® , Dutscher, France) at 2 x 10 6 viable cells per well. Forty eight hours after seeding, treatment with CPZ was started. The culture medium consisted of Hepatocyte Maintenance Medium (HMM™) supplemented with 1 % ITS, 100 nM dexamethasone and 50 µg/mL gentamycin. Medium was renewed every day and a new overlay with Geltrex TM (350 µg/mL) was applied 6, 9 and 13 days after seeding. onto a QIAshredder spin column (Qiagen) and centrifuged for 2 min at 13800 g to be sure of full homogenization. The lysates were kept at -80°C until RNA extraction.
Total RNA was extracted using the RNeasy Plus Mini Kit from Qiagen (Hilden, Germany) on the automated QIAcube™ robotic workstation (Qiagen), both according to the manufacturer's protocols.
The RNA quantity was assessed with the NanoDrop 2000 (Thermo Fisher Scientific, Waltham (MA), USA), while the quality was determined with the Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany).
Transcriptomics Processing
Biotinylated cRNA was amplified with the Illumina ® TotalPrep™-96 RNA Amplification kit GenomeStudio ® Data Analysis Software (Illumina) was used to check the quality of the transcriptomic raw data and to make it accessible for further processing (Illumina, 2010) . Transcriptomic raw data were log2 transformed and quantile normalized before statistical analysis. Quantile normalization was performed as outlined in Bolstad et al. (2003) given donor varied between 0 and 9, suggesting little biological significance for these genes. Indeed, these were pseudogenes and genes involved in cellular homeostasis (e.g. PCK1 and HNRNPA2B1)
that were not included in the hepatic signatures described hereafter. This large variability indicates that a global analysis of gene expression data only makes sense when looking at each donor in isolation.
This article has not been copyedited and formatted. The final version may differ from this version. (table 2) . Cholestasis, fibrosis, hepatitis, inflammation, liver proliferation, necrosis, GSH depletion and steatosis were identified both after short-term (1 or 3 days) and long-term (14 days) CPZ treatment, while genes related to the pathway giving rise to a signature of cirrhosis were deregulated only after 14 days.
These IPA ® -derived hepatic signatures were thereafter expanded by further deregulated genes known to be involved in liver toxicity as illustrated in Figure 3 . Signatures of liver inflammation/hepatitis, liver proliferation and cholestasis were present in all donors. Cholestasis-related genes were observed as early as the first exposure and in 5/5 donors, this effect was maintained over the entire treatment time. Signatures of fibrosis/cirrhosis, and steatosis were present in 4/5 donors and steatosis was represented with a minimum of one deregulated gene after short-term treatment and two deregulated genes after prolonged treatment. Necrosis/GSH depletion/oxidative stress was present in 3/5 donors.
Even though the hepatotoxicity signatures were to some degree present in all donors, differences could be highlighted: for example, PHH donor S251110 showed signs of necrosis only after short-term treatment with CPZ but no signs of fibrosis/cirrhosis, indicating only transient effects. PHH donor S301110 showed signs of fibrosis only after short-term treatment and no signs of cirrhosis, whereas liver inflammation appeared only after long-term treatment and no signs of necrosis were seen. PHH donor S1045 gave no signs of steatosis or necrosis. PHH donor B1050 showed no induction of steatosis after long-term treatment. PHH donor M291110 was the only donor showing all hepatic signatures both in short-and long-term CPZ treatment.
In order to better capture the time-dependent and donor-dependent hepatotoxicity response to CPZ treatment, we compared the number of gene expression changes across hepatic signatures, donors and Of particular relevance was the fact that at 1 and 14 days of CPZ treatment, donors with a large number of gene changes related to liver inflammation/hepatitis (M291110 and B1050) also showed large numbers of gene changes related to other specific hepatotoxic signatures.
With treatment concentrations of 0.02 µM (i.e. 1/10 th of Cmax (n = 3)) fewer gene changes were observed and with 1 µM (i.e. 10-fold Cmax (n = 2)) more gene changes were observed, but 85 % and 66 % of those genes were also deregulated with Cmax (0.1 or 0.2 µM) treatment concentrations, respectively (data not shown). Therefore, we can conclude that whatever the concentration used the hepatic signatures were overall similar (Table 2) indicating that we could not define a concentration that did not induce adverse effects. Genes related to necrosis, GSH depletion, steatosis, fibrosis, cholestasis, inflammation, hepatitis and liver proliferation pathways were deregulated both after shortand long-term treatment. Signs of cirrhosis were observed both after short-and long-term of treatment with 1 µM of CPZ, while at 0.1 and 0.2 µM signs of cirrhosis appeared only after 14 days of treatment.
Discussion
After a 14 day treatment period with increasing concentrations of CPZ, the highest non-cytotoxic concentration observed in PHH was between 0.2 and 1 µM. These results are in accordance with the TC 50 (9 ± 6 µM after 48 hours of treatment in PHH) reported by Gerets et al. (2012) . The fact that these concentrations of CPZ are close to the reported Cmax levels in humans (Borges et al., 2011) prompted us to choose PHH repeat-treatment concentrations of 0.1 or 0.2 µM (n = 5), as well as 1/10 th (0.02 µM, n = 3) and the 10-fold concentration (1 µM, n = 2) for transcriptomics analysis.
In the present study, we found that after 3 days of treatment fewer gene changes were induced compared to days 1 and 14. We (Richert et al., 2009) have previously described that genes deregulated after 24 hours treatment are not automatically deregulated after 72 hours, and this could represent an adaptation phase after the primary acute response on day 1. Nevertheless, repeat exposure for up to 14 days provided valuable additional information in some donors (S251110, M291110 and S1045) and gave further insight into the mechanism of long-term CPZ induced hepatotoxicity.
The CYP1A gene, one of the main CYP450 involved in CPZ metabolism (Wojcikowski et al., 2010) and producing a metabolite more toxic than the parent (Tavoloni and Boyer, 1980) , was found to be up-regulated in the present study after the first day and up to 14-days of treatment at 0.1 and 0.2 µM (2-fold) and 1 µM (3-fold) in PHH. However, other mechanisms than increased CYP1A1/2-reactive metabolite formation are involved in CPZ cytotoxicity towards human hepatocytes, since a similar increase was observed in rat hepatocytes exposed to 1 µM CPZ without any overt signs of cytotoxicity (unpublished data). Inter-individual CYP2D6 dependent reactive metabolite formation seems not to be directly related to toxicity. Indeed, donor B1050 displayed the highest expression in CYP2D6
(between 3-to 9-fold that of the 4 other donors) and a CYP2D6 activity of 1.5 pmol/min/mg cell protein compared to 0.5 pmol/min/mg cell protein for donor S1045, but was not more susceptible to CPZ toxicity than the latter (see also discussion below).
The global hepatic signature obtained after 0.1 or 0.2 µM CPZ treatment generated using the Ingenuity Pathway Analysis ® (IPA) software was comparable in the five PHH cultures. Cholestasis is the main DMD # 52415
1 5 form of hepatotoxicity described in patients treated with CPZ, with an incidence of 1-2 % after treatment with therapeutic doses (Boelsterli et al., 1987; Regal et al., 1987) . In 5/5 donors the gene expression changes are indicative of, according to IPA analysis, the cholestasis pathway. The hepatocyte uptake transporter NTCP (SLC10A1) has been described to be down-regulated during cholestasis (Lee and Boyer, 2000; Zollner et al., 2001) . In the present study, NTCP (SLC10A1) was down-regulated in 3/5 donors, after the first day of treatment at 0.02 and 0.2 µM (M291110 and S301110) and after 14-day of treatment at 0.1 µM (S1045). OCT (SLC22A1) was down-regulated in 2/5 PHH donor exposed to short-(M291110) and long-term (S1045) 0.1 or 0.2 µM CPZ. The expression of the hepatocyte efflux transporter BSEP (ABCB11) has been reported to be either decreased (Zollner et al., 2001) or not affected (Lee and Boyer, 2000; Demeilliers et al., 2006) in patients with liver cholestatis. In the present study, BSEP, p-gp (ABCB1) and BCRP (ABCG2) were not transcriptionally deregulated at any treatment time in any of the donors after CPZ treatment. Since CPZ is known to inhibit uptake transporters, such as OCT1 (SLC22A1) and also efflux transporters such as BSEP (ABCB11), p-gp (ABCB1) and BCRP (ABCG2) (Pedersen et al., 2008) , the results of the present study suggest a cellular feed-back regulation at the transcriptional level of the uptake but not secretory transporter proteins to counteract the inhibition of canalicular transport of bile acids.
Down-regulation of CYP7A1, which is a major CYP450 involved in bile acid synthesis (Demeilliers et al., 2006) , has also been described in cholestatic patients. CYP7A1 was deregulated in 3/5 donors, up-regulated in two donors, after short-term (B1050) or long-term treatment (S251110) and downregulated in M291110 after long-term treatment. Taken together, these data highlight feed-back regulations at the transcriptional level by human hepatocytes exposed to CPZ reflecting their attempts to reverse disturbances in bile acid homeostasis.
Fibrosis degenerating into cirrhosis was also described in patients with a lower sulfoxidation capacity (Larrey and Pageaux, 1997; Brind, 2007) . Indeed, sulfoxidation mediates CPZ detoxification (Wojcikowski et al., 2010 ) and a poor capacity of sulfoxidation leads to an accumulation of toxic metabolites that could cause fibrosis and, eventually cirrhosis. From the five studied PHH donors, two signs of cirrhosis whereas in two other donors (S1045 and B1050) fibrosis and cirrhosis were highlighted both after short and long-term treatment, which might suggest a poor capacity of sulfoxidation in these donors. Our data did not indicate expression changes of genes involved in sulfoxidation, suggesting that changes at the post-translational level, not measurable by transcriptomics, might possibly lead to these adverse effects.
Signs of liver steatosis were also evident in PHH cultures treated with CPZ: up-regulation of the CYP2E1 gene in 3/5 donors (M291110, S301110, S1045) and of the CYP4A11 gene in 2/5 donors (M291110 and S301110), two markers involved in lipid metabolism and known to be induced in patients with steatohepatitis (Jansen, 2004) .
In the present study, transcriptomic data showed gene expression changes related to signs of necrosis, possibly due to the treatment with a concentration close to the TC 10, thus causing cell damage.
S251110 PHH culture showed signs of necrosis only after short-term treatment whereas M291110 and B1050 showed these signs both after short-and long-term treatment. Liver regeneration has been described to be a defense mechanism of the liver to cytotoxicity (Lee, 2003; Hinson et al., 2010) . The early signaling components TNFα and IL-6 secretion are known to cause up-regulation of genes involved in liver regeneration, such as STAT1, MAPK, or IGFBP1 and also up-regulation of vascular endothelial growth factor gene (VEGF) (Li et al., 2002) . In the present study a strong up-regulation of IL-6 was accompanied by an up-regulation of MAPK9, IGFBP1, IL1RN and VEGFA (M291110) or STAT1 (S1045), while down-regulation of TNFα and IL-6 genes was accompanied by a downregulation of IGFBP1, IL1RN and STAT1 genes (B1050). All of these genes involved in liver regeneration were hardly affected when early signaling was not or only slightly deregulated (S251110 and S301110).
IL-6 and TNFα are also widely described to promote inflammatory events through the expansion and activation of T-cells, differentiation of B-cells, and the induction of acute-phase reactants by hepatocytes (Jones et al., 2001 ). TNFα gene polymorphisms are known to result in variable TNF production which leads to inter-individual drug toxicity in human (Louis et al., 1998) . Interestingly, DMD # 52415
when an inflammatory event was induced prior to CPZ treatment, cholestasis could be induced in rats (Buchweitz et al., 2002) . In the present study, up-regulation of IL-6 gene expression (M291110 and S1045) was accompanied by an up-regulation of the IL-8 gene, another interleukin induced during liver inflammation, as well as several chemokines and chemokine receptors, such as CCL2 or CXCL2
genes. When the IL-6 gene was down-regulated (B1050), many chemokine and receptor genes were also down-regulated and when the IL-6 gene was not deregulated (S251110 and S301110), no other genes of this IL-6 dependent inflammatory pathway were deregulated. It is also noteworthy that donors with TNF/IL-6 deregulated pathways (M291110, S1045 and B1050) presented more genes deregulated in other pathways, including cholestasis and fibrosis/cirrhosis. Taken together, these results support the hypothesis that features of inflammation could be related to the idiosyncratic effects of CPZ (Roth et al., 2003) In summary, short-and long-term in vitro exposure of PHH to CPZ at concentrations close to human 
